TrialJAMA cardiology2019

Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.

Gregg C Fonarow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.